Geron Corporation
NASDAQ: GERN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Harout Semerjian
- Employees
- 229
- Headquarters
- Foster City, United States
- IPO year
- 1996
- Market cap
- $888.5M
- Website
- https://www.geron.com
Loading GERN…
Loading profile data…Frequently asked questions about GERN
What does Geron Corporation (GERN) do?
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem...
Where does GERN trade?
Geron Corporation (GERN) trades on the NASDAQ Global Select.
What sector is GERN in?
Geron Corporation (GERN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Geron Corporation?
Harout Semerjian is the chief executive officer of Geron Corporation (GERN).
Where is Geron Corporation headquartered?
Geron Corporation is headquartered in United States.
Does GERN pay a dividend?
Geron Corporation (GERN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GERN go public?
Geron Corporation (GERN) completed its initial public offering in 1996.